Almost everyone can expect to experience some degree of hair loss during chemotherapy. Scalp cooling is an effective method for reducing the risk of chemotherapy-induced hair loss in men and women with solid tumor cancers. The outcome is dependent on several factors including the chemotherapy regimen, dose, duration of drug infusion, chemotherapy drug metabolism and other medical considerations. 

Scalp cooling has been evaluated mainly with regimens including taxanes (such as paclitaxel and docetaxel) and anthracyclines (such as doxorubicin and epirubicin). It’s not always possible to know how effective the scalp cooling outcome will be until you try it. The effectiveness of scalp cooling with chemotherapy regimens that include sequential anthracycline and taxane chemotherapy in the same infusion day has not been well studied. Your clinician can tell you if scalp cooling is compatible and likely to be successful with your treatment.